BiotechTube

Etoposide

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma, Kaposi

Conditions

Sarcoma, Kaposi, HIV Infections

Trial Timeline

— → Jul 1, 2000

NCT ID
NCT00000807

About Etoposide

Etoposide is a phase 2 stage product being developed by Bristol Myers Squibb for Sarcoma, Kaposi. The current trial status is completed. This product is registered under clinical trial identifier NCT00000807. Target conditions include Sarcoma, Kaposi, HIV Infections.

What happened to similar drugs?

1 of 15 similar drugs in Sarcoma, Kaposi were approved

Approved (1) Terminated (1) Active (13)
🔄Abemaciclib + PlaceboEli LillyPhase 3
🔄cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
🔄Trabectedin + Doxorubicin + IfosfamideJohnson & JohnsonPhase 3
❌LV305 + G305MerckPhase 3
✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00000660Phase 1Completed
NCT00000807Phase 2Completed

Competing Products

20 competing products in Sarcoma, Kaposi

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
19
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
22
AbemaciclibEli LillyPhase 2
39
Abemaciclib + PlaceboEli LillyPhase 3
44
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
44
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
24
exatecan mesylateDaiichi SankyoPhase 2
35
efatutazoneDaiichi SankyoPhase 2
35
soblidotinDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
LinsitinibAstellas PharmaPhase 2
35
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
31
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
42
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
42
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
EribulinEisaiPhase 2
39
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
35